HALO:NASDAQHalozyme Therapeutics, Inc. Analysis
Data as of 2026-10-02 - not real-time
$106.94
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Halozyme Therapeutics, Inc. trades at $106.94, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. With RSI at 47.2 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at $105.50 and resistance at $116.85.
Valuation screens as overvalued: a P/E of 32.4 sits in line with the sector average of 29.7. Analyst price targets sit 6.9% below the current price. Revenue is growing at 47.7% on a 24.9% profit margin.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 25.7%, a beta of 0.53 and a maximum drawdown of 24.1%, position sizing matters here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Valuation screens as overvalued: a P/E of 32.4 sits in line with the sector average of 29.7. Analyst price targets sit 6.9% below the current price. Revenue is growing at 47.7% on a 24.9% profit margin.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 25.7%, a beta of 0.53 and a maximum drawdown of 24.1%, position sizing matters here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Top Market Events
Halozyme Therapeutics, Inc. Nasdaq: HALO "Halozyme" or the "Company" , today announced that it intends to offer,...Halozyme Therapeutics, Inc. NASDAQ:HALO announced on September 16 a proposed $1.05 billion offering of convertible...The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 78.10
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 32.4 versus sector average of 29.7
- Trading above the 200-day average of 78.10
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 32.4 versus sector average of 29.7
- Analyst targets imply -6.9% versus the current price
- Profit margin of 24.9% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth47.70%
Profit Margin24.86%
P/E Ratio32.4
ROE173.67%
ROA25.49%
Debt/Equity1517.69
P/B Ratio84.9
Op. Cash Flow$818.6M
Free Cash Flow$337.3M
Industry P/E29.7
Technical Analysis
TrendBullish
RSI47.2
Support$105.50
Resistance$116.85
MA 20$110.28
MA 50$102.35
MA 200$78.10
MACDBearish
VolumeIncreasing
Fear & Greed Index92.16
Valuation
Fair Value$77.95
Target Price$99.56
Upside/Downside-6.91%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.53
Volatility25.67%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.